Company: ZURA
Filing Date: 2025-05-28
Form Type: SCHEDULE 13D
Source: 0000950170-25-078447
Chunk: 1

Company: Zura Bio Ltd
Filing Date: 2025-05-28
Form: SCHEDULE 13D
Chunk 1
---
the "2024 Subscription Agreement"). AIB funded this purchase using capital contributed from affiliated entities, which funded that capital using cash on hand. Under the terms of the 2024 Subscription Agreement, the Issuer agreed to prepare and file with the SEC, within 35 days after the closing, a registration statement to register for resale the Class A Ordinary Shares issuable upon exercise of the 2024 Warrants (the "2024 Warrant Shares"), and to cause the registration statement to become effective within a specified period after the closing. The Issuer also agreed to use its best efforts to keep such registration statement effective until the earlier of (i) the date on which all of the 2024 Warrant Shares held by or issuable to AIB may be sold under Rule 144 without being subject to any volume or manner of sale requirements, (ii) the date on which all of the 2024 Warrant Shares have actually been sold pursuant to Rule 144 or pursuant to the registration statement and (iii) the date which is two years from the date that the initial registration statement is declared effective (or any Additional Effectiveness Date (as defined in the 2024 Subscription Agreement), if applicable).                                                                                                                                                                                                                                                                                                                                                    
 On November 24, 2024, AIB purchased from Athanor Master Fund, LP ("AMF") and Athanor International Master Fund, LP ("AIMF") 500,000 Class A Ordinary Shares at a price of $2.73 per share, pursuant to a purchase and sale agreement between AMF, AIMF and AIB dated as of November 24, 2024 (the "2024 Purchase Agreement"). AIB funded this purchase using capital contributed from affiliated entities, which funded that capital using cash on hand.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 On April 17, 2025, AIB (i) surrendered 3,000,000 Class A Ordinary Shares, for no consideration and (ii) the Issuer issued to AIB 3,000,000 private placement pre-funded warrants, each whole pre-funded warrant entitling AIB to purchase one Class A Ordinary Share at an exercise price of equal to $0.001 per share (the "2025 Warrants" and together with the 2023 Warrants and the 2024 Warrants, the "Private Placement Warrants"), pursuant to a share surrender and warrant agreement between the Issuer and AIB dated as of April 17, 2025 (